• SGSI sees a dynamic market opportunity in new 5G site projects
• A spike in installation demand combined with limited qualified services firms could result in a financial opportunity for SGSI
• The company reported positive income from operations during the first quarter of 2019

Spectrum Global Solutions Inc. (OTCQB: SGSI) says that its bundling of services and the low number of qualified services firms in the growing telecommunications market helped drive higher revenues and growth in its margin potential on projects in the first quarter of 2019 (http://ibn.fm/XUSUd).

Notably, SGSI reported first quarter revenues of $11,335,732 for the three months ended March 31, 2019, as compared to $4,327,764 for the first quarter of 2018 (http://ibn.fm/6G25a). First quarter numbers also showed SGSI achieving its first quarterly positive income from operations of $14,699 in Q1 2019, as compared to a loss from operations of $743,491 for the comparable period in 2018.

The combined gross profit reported in Q1 from subsidiaries acquired in April 2017, February 2018 and January 2019 was $2,511,567, marking a 22.2 percent gross profit increase. By comparison, in the first quarter of 2018, the company’s gross profit was $543,244.

SGSI sees market growth in future 5G implementation from telecom companies, as well as ongoing 4G network upgrades. The company has positioned itself to gain more market share and will seek to maximize cross-selling opportunities by leveraging services and relationships with clients of operating subsidiaries. The peak in market installation demand and low number of qualified services firms could result in SGSI expanding 2019 revenues, driven by strategic, accretive acquisitions and organic growth.

SGSI is a leading provider of telecommunications engineering and infrastructure services in the United States, Puerto Rico, Canada, Guam and the Caribbean. The company sees an intriguing opportunity as new 5G sites expand wireless coverage and 4G sites continue to require maintenance and upgrades. SGSI subsidiaries include AW Solutions, ADEX TNS and Tropical Communications Inc.

SGSI is a single-source provider of wireless and wireline network infrastructure and professional service solutions to the service provider (carrier) and corporate enterprise markets. The company builds and services end-to-end communication networks (http://ibn.fm/07Yl7).

For more information, visit the company’s website at www.SpectrumGlobalSolutions.com

NOTE TO INVESTORS: The latest news and updates relating to SGSI are available in the company’s newsroom at http://ibn.fm/SGSI

• Earth Science Tech is a biotechnology company offering high-grade cannabinoids
• ETST has diverse subsidiaries that promote the company’s role as a leader in the CBD sector
• Earth Science Tech has various partnerships and distribution agreements in place

Earth Science Tech Inc. (OTCQB: ETST) operates in the hemp cannabinoid, nutraceutical, pharmaceutical and medical device research and development fields. A biotechnology company headquartered in Doral, Florida, ETST markets high purity and quality full-spectrum cannabinoids. The company’s wholly owned subsidiaries – including Earth Science Pharmaceutical Inc., Cannabis Therapeutics Inc. and Canna Inno Laboratories Inc. – concentrate on developing Earth Science Tech’s role as a worldwide leader in the CBD sector.

The company’s management team consists of experienced industry experts from the nutraceuticals, dietary supplement and life sciences fields. Earth Science Tech is developing new products and has secured several partnerships, with strategic plans to extend its footprint within the medical cannabis market. These partnerships will enable the company to develop new and novel cannabinoid-based pharmaceutical and nutraceutical products (http://ibn.fm/P4T2M).

Wholly owned subsidiary Earth Science Pharmaceutical develops low-cost, non-invasive diagnostic tools, medical devices, testing processes and vaccines for sexually transmitted infections and diseases (STIs). The executive team of Earth Science Pharma has years of scientific, medical and business experience in the health, research and manufacturing fields. The subsidiary is working to develop and bring to market medical devices and vaccines that meet the specific needs of women.

Earth Science Pharma’s first medical device is MSN-2, a home kit designed for the detection of STIs, such as chlamydia, from a self-obtained gynecological specimen. Earth Science Tech is advancing clinical testing of MSN-2 via a collaborative agreement with Laboratories BNK Canada (http://ibn.fm/Ckn54).

Wholly owned subsidiary Cannabis Therapeutics is working to take a leadership role in the development of new, cutting-edge, cannabinoid-based pharmaceutical and nutraceutical products. The company is invested in research and development to explore and harness the medicinal power of cannabidiol. Cannabis Therapeutics is also working to integrate the CBD molecule with existing generic drug molecules. The company’s mission is to help change the health care landscape by introducing its proprietary cannabis/cannabinoid-based products made for the global pharmaceutical and retail consumer markets.

Established in 2017, Canna Inno Laboratories is Earth Science Tech’s Canadian subsidiary, based in Montreal, Québec. The company’s mandate is to give ETST a foothold in Québec and provide the company with access to government grants offered to innovators in the pharmaceutical industry. One grant has been approved so far.

Earth Science Tech’s medical and industrial hemp products are made from high-grade, full-spectrum cannabinoids that are extracted using the supercritical CO2 liquid process. All of the company’s full-spectrum cannabinoids are mixed in coconut MCT oil to ensure the best delivery and absorption, and its offerings include CBD, CBDa, CBG, CBGa, CBN, CBC and CBDV; the cannabinoids also contain terpenoids, aminos, omegas, saponins and flavonoids.

Earth Science Tech has entered into agreements with CannaBiz and Desert Sun Distribution (http://ibn.fm/xknKJ) for the distribution of the company’s high-grade, full-spectrum cannabinoids line throughout pharmacies, chiropractors, dispensaries, athletic clubs and clinics in the United States.

“We see tremendous synergy between our CBD line and the health care practitioner and pharmacy spaces,” ETST Chief Sales Officer David Barbash stated in a news release. “The distribution agreements with CannaBiz and Desert Sun Distribution, while important, are only a fraction of the opportunities we see for our CBD products.”

Earth Science Tech continues to develop its diverse portfolio and pipeline. The company offers investors the opportunity to be part of the burgeoning cannabinoid-based pharmaceutical and nutraceutical products market as it expands its role as a leader in different sectors. Earth Science Tech remains dedicated to developing leading-edge pharmaceutical and medical device offerings.

For more information, visit the company’s website at www.EarthScienceTech.com

NOTE TO INVESTORS: The latest news and updates relating to ETST are available in the company’s newsroom at http://ibn.fm/ETST

• INmune Bio is at the vanguard of reprogramming the innate immune system for the treatment of disease
• The company’s focus is on modulating components of the innate immune system to treat cancer and Alzheimer’s disease
• INmune Bio’s drug candidates include INKmune, INB03 and XPro1595

INmune Bio Inc. (NASDAQ: INMB) is a diversified, clinical-stage biotechnology company headquartered in La Jolla, California. The company is hoping to develop new immunotherapies that reprogram patients’ innate immune systems to allow the immune systems to fight cancer and Alzheimer’s disease. INmune drug candidates INKmune and INB03 may be used to treat cancer, while XPro1595 targets neuroinflammation as a cause of Alzheimer’s disease.

INmune Bio’s vision is to become the leader in reprogramming the innate immune system for the treatment of disease. Innate is an immediate, nonspecific, initial response that serves as a first line of defense against infection and cancer. Most drug-development programs concentrate on the adaptive immune response and ignore innate immunity. INmune Bio harnesses the innate immune system with a targeted biomarker approach.

The company’s INKmune drug is a biologic therapy. INKmune primes NK cells to eliminate minimal residual disease, which is a major cause of cancer relapse and death. NK cells play a vital role in preventing cancer. Later this year, the company expects to begin enrolling patients in a phase I/II trial for women with relapsed refractory ovarian cancer.

INKmune is delivered by simple IV infusion, allowing for the delivery of critical priming signals to patients’ resting NK cells. Once in the system, INKmune encounters resting NK cells. The interaction converts NK cells to primed NK cell (“PiNK”), much like an on-off switch. PiNK then remain primed until they contact and kill cancer cells (http://ibn.fm/zb0GM).

INmune Bio’s INB03 is a protein biologic. The company believes that INB03 could have numerous beneficial effects in patients with cancer. INmune Bio’s initial emphasis is on its ability to inhibit the proliferation and function of myeloid-derived suppressor cells (“MDSC”). By preventing the proliferation and function of MDSC, the company believes that patients will have a stronger immune response to cancer cells.

INmune Bio also believes that INB03 treatment may help patients better respond to other cancer treatments, including immunotherapy. INB03 is a PEGylated protein therapeutic administered as a once-weekly subcutaneous injection, similar to an insulin shot (http://ibn.fm/Dql3j). This summer, the INB03 program will transition into a combination therapy clinical program to prepare for a phase II trial to research patients’ resistance to checkpoint inhibitors because of increased MDSC.

The company’s XPro1595 is a protein biologic that targets soluble TNF (“sTNF”). XPro1595 may trigger many beneficial effects in patients with Alzheimer’s disease by reducing neuroinflammation. XPro1595 targets the microglial immune cells of the brain, which are responsible for neuroinflammation and are activated in many Alzheimer’s disease patients.

INmune Bio continues to develop its product platforms that use a precision therapy approach. The company offers investors the potential for significant ROI as it targets large markets with unmet needs. With its programs in oncology and neurodegenerative disease, INmune Bio is focusing on multiple opportunities that provide sum-of-parts value.

For more information, visit the company’s website at www.INmuneBio.com

NOTE TO INVESTORS: The latest news and updates relating to INMB are available in the company’s newsroom at http://ibn.fm/INMB

• Geyser Brands is entering into a definitive agreement for the acquisition of Solace Management Group for an aggregate purchase amount of $3.9 million
• The acquisition will enable Geyser to broaden the scope of its CBD- and hemp-based product range, helping solidify its position on the international market
• Solace has an extensive portfolio of pet and consumer products, as well as licensing distribution and production arrangements

Consumer health care company Geyser Brands Inc. (TSX.V: GYSR) recently announced its entry into a definitive agreement for the acquisition of Solace Management Group Inc., a private corporation existing under the laws of British Columbia.

The acquisition is strategic for Geyser Brands, company CEO Andreas Thatcher said in a news release (http://ibn.fm/eJ6DA). It is expected to establish Geyser as a leading provider of health-focused CBD and hemp products. Established brand companies like Solace have developed deep connections with their customers, Thatcher concluded, providing Geyser with an opportunity through its cannabis licensed producer to extend that conversation into CBD.

Solace has well-established brands already operating in the cannabis space. The company has gained significant market share through proprietary formulations and distribution and production arrangements.

One of the company’s most prominent brands is all-natural hemp-based pet treats line Apawthecary Pets. The products are available in pet and veterinary stores across Canada. Solace’s portfolio also features 23 products and 57 SKUs of both pet and consumer health care formulations. All of the products are made from organic, cold-pressed hemp seed oil.

The company has a steady expansion strategy in place. Recently, Solace moved to a new 7,500 sq. ft GMP-compliant facility that significantly increased its production capacity.

Even more significant, however, is the company’s more than C$2 million in 2018 revenues, with net margins of 30 percent. This shows an unusual level of product development and market acceptance.

As per the new definitive agreement with Geyser Brands, Solace will be terminating its licensing agreement with the company’s current Canadian manufacturer. Manufacturing and distribution will both become internal processes for the purpose of revenue maximization. The Solace licensing agreement with the company’s U.S. manufacturer is on hold. The manufacturer has to obtain all required regulatory approvals and licenses to comply with applicable laws.

The terms of the agreement between the two entities state that Geyser Brands will acquire all of the issued and outstanding shares of Solace for an aggregate purchase amount of $3.9 million. Closing of the proposed transaction remains subject to Geyser’s satisfaction of the Solace due diligence review, the receipt of necessary (third-party) consent, board approvals, shareholder approval, TSX Venture Exchange approval, satisfaction of exchange requirements, etc.

Geyser Brands is a health care company with a focus on Hemp CBD-based consumer products. Through its Health Canada-approved licensed producer in Vancouver, British Columbia, it is building a regulatory platform for the manufacture and distribution of cannabis products in Canada, and it is anticipating its processing and sales licenses.

These will be become the channel though which brands can reach consumers in the regulated space. The company plans to roll out this business model globally, where CBD regulations allow, particularly in Asia and Europe.

Investment in product innovation includes the company’s proprietary nanotechnology, NanoFusion, which delivers topical, cream, food, beverage, oil, tincture and baked good formulations with superior bio availability, water solubility and dosage control.

For more information, visit the company’s website at www.GeyserBrands.com

NOTE TO INVESTORS: The latest news and updates relating to GYSR are available in the company’s newsroom at http://ibn.fm/GYSR

• VPR Brands’ quarterly revenues are up by 31 percent
• The company maintains healthy gross operating margins in excess of 40 percent
• The e-cigarette/vapor market is estimated to hit $9 billion in 2019

Recent financial results released by VPR Brands LP (OTC: VPRB) show that the multi-brand developer and marketer of nicotine and cannabis products has what it takes to scale up successfully. Revenues for the first quarter of 2019 are up, year-over-year, approximately 31 percent, continuing the trend from the year before, when the top line for 2018 climbed to $4,613,300 and marked a 28 percent increase over 2017 revenues of $3,610,379. If the innovative provider of smokeless cannabis and nicotine products maintains its current gross operating margins in excess of 40 percent, break-even doesn’t seem very far away.

VPR’s product portfolio positions the company to capitalize on lofty projections for the e-cigarette/vapor market, as well as the fledgling cannabis industry. Notably, the cannabis sector is still far from maturity. In 2016, the last year for which data is available, just 16 percent of the population aged 15-64 reported using cannabis at least once in the past year. As the wave of liberalization and legalization progresses, that percentage is expected to rise. In addition, driven by an increasing awareness of the negative effects of smoking, consumers are switching to smokeless products. As a result, the e-cigarette market is expected to reach $6.4 billion in 2019.

The company’s flagship brand – HoneyStick – targets both the nicotine and cannabis markets. The company is betting heavily on the lifestyle brand to drive growth in both verticals. The HoneyStick platform was developed with the vaping enthusiast in mind and has evolved through in-house product development to suit the needs of both cannabis and nicotine consumers. The line, consisting of vaporizers, vape tanks and accessories, is a High Times award-winner. Krave, Helium, VaporX and Vaporin are ancillary brands that cater to the nicotine vertical, while the company has entered the CBD vertical through its Goldline CBD product line.

The Goldline range is presently available in 15 SKUs that include CBD gummies, CBD pens, CBD oil and CBD extracts. The high potency Goldline gummies provide quick activation and strong onset of CBD. Each gummy uses a high-quality CBD glaze so that activation begins immediately on contact with the tongue. The Goldline CBD vape pens are pre-loaded, ready to vape devices. They’re also disposable. When the tank runs dry, you can simply toss the pen and buy another one. The pens contain 100mg of pre-loaded pharmaceutical grade CBD that comes in four flavors.

Goldline CBD crumble is a full spectrum extract that is rich in CBD. Its 250mg power-packed filling delivers CBD immediately, with unmatched potency. Extracted from the highest grade of CBD flower, the product comes in a solid format, which allows it to be placed and vaped on an open coil vaporizer. The Goldline range also includes CBD oils and tinctures that come in 30ml bottles.

A strong management team holds the reins at VPR Brands LP. The company’s chief executive officer is Kevin Frija, a veteran entrepreneur with three decades of experience in advertising, brand licensing, marketing and supply chain management. In 2009, Frija became the president and chief executive officer of Vapor Corp., a publicly traded electronic cigarette company and e-cigarette importer, which, in 2014, uplisted to the Nasdaq Capital Market. In 2016, Vapor Corp. sold its brands and wholesale business assets to Frija. They are presently owned by VPR Brands LP.

Dan Hoff is the chief operating officer of VPR Brands LP. He previously worked at Vapor Corp. under Kevin Frija, overseeing finance and accounting, supply chain management, product design and development and key vendor relations. Hoff also helped build and expand Vapor Corp.’s cannabis-based products division and expand its wholesale division. More recently, he worked to develop and expand Vapor Corp.’s medical cannabis vape program, which provides turnkey OEM vapor solutions for cannabis farmers, cultivators and extractors.

For more information, visit the company’s website at www.VPRBrands.com

NOTE TO INVESTORS: The latest news and updates relating to VPRB are available in the company’s newsroom at http://ibn.fm/VPRB

• Anticipating Canadian legalization of adult-use cannabis edibles in October 2019, Organigram recently announced a C$15 million investment commitment in a high-speed, high-capacity, fully automated chocolate line
• Production capacity is expected to be about 4 million kilograms per year of exceptional chocolate cannabis edibles
• The company’s chocolate launch is being led by a product development and production team with more than 25 years of combined chocolate experience and expertise

Canada is drawing closer to the legalization of edibles and derivative products, which is expected to occur this fall. As noted by Green Entrepreneur, edibles are expected to increase to 12-14 percent of the total cannabis market in Canada and the U.S. by 2022 (http://ibn.fm/5dB6x). The pending rise of the edibles sector is good news for companies such as Organigram Holdings Inc. (TSX.V: OGI) (NASDAQ: OGI) that are positioning themselves to capture this further growth opportunity.

Organigram recently announced a C$15 million investment commitment for a state-of-the-art chocolate molding line and a fully integrated packaging line that includes advanced engineering, robotics, high-speed labeling and automated shipping carton packing. According to the company’s statement, the production line is expected to produce chocolate innovations that are not only unique to the cannabis industry, but to the chocolate industry as a whole.

“Over the last number of years, Organigram has become known for its best-in-class cannabis production facility and high-quality products. With this investment, we will soon also be known for our world-class chocolate production capability,” Organigram CEO Greg Engel stated in a press release announcing the investment (http://ibn.fm/cR5Yy).

On May 21, 2019, Organigram hit another company milestone when shares of its common stock began trading on the Nasdaq under ticker symbol ‘OGI’ (http://ibn.fm/pNuWR), in addition to its listing on the TSX Venture Exchange under the same symbol.

As a leading Canadian licensed producer of high-quality cannabis and extract-based products, Organigram is focused on producing indoor-grown cannabis for patients and adult recreational consumers in Canada, as well as developing international business partnerships to expand the company’s global footprint.

For more information, visit the company’s website at www.Organigram.ca

NOTE TO INVESTORS: The latest news and updates relating to OGI are available in the company’s newsroom at http://ibn.fm/OGRMF

• The company maintains the top two best-selling edible cannabis products in California
• Plus is working to make cannabis safe and approachable for all
• The company recently reported a 4.9 percent increase in sales over Q4 2018, bringing Q1 2019 retail sales to $10.84 million
• Plus recently commenced trading on the OTCQX Best Market

Plus Products Inc. (CSE: PLUS) (OTCQX: PLPRF) recently released its unaudited first quarter 2019 results (http://ibn.fm/ZS4tn). As the edibles’ share of the cannabis market continues to grow, PLUS is well positioned to lead the way in the branded products space. The company is one of the fastest-growing brands in the California market and produces two of the top-10 cannabis edibles products in the state. California is the most competitive cannabis market, due, in large part, to its long history of medical legalization.

PLUS creates high-quality, precisely dosed products that bring balance to people’s lives. Customers know what they are getting every time they reach for a PLUS gummy or mint. This consistency keeps customers coming back and is a key factor in why PLUS held the spot for the best-selling and second best-selling edible products in California in both dollars and units sold. PLUS “Uplift” was the top-selling branded product of more than 13,700 products sold across all categories in California, according to Headset (http://ibn.fm/MSOpO).

While the gummies continue to hold the top-two slots for edibles, PLUS launched a new microdose product line earlier this year. The new mints complement the already-successful gummies, providing the same Create, Uplift and Restore elevation but at a lower dose of only 2.5mg of active ingredients per piece. The mints were launched at the Hall of Flowers cannabis trade show on April 30, 2019.

“Mints are a logical extension to the PLUS product family as more customers seek out unique taste experiences and low-dose products they trust,” Plus Products CEO and co-founder Jake Heimark stated in a news release (http://ibn.fm/bFMn1). “We are excited about giving customers the best experience and will continue to be the leader in low-dose infused products in THC.” The company continues to provide low-dose cannabis edibles, which now include options for the microdosing movement that consumers continue to revisit.

PLUS believes strongly that cannabis should be safe and approachable for everyone and is actively involved in the National Cannabis Roundtable. Taking on leadership roles within the roundtable, company officials are working to help structure laws that align with these values.

The company has also redesigned its signature tins in new, child-resistant packaging, meeting government regulations one full year before the 2020 deadline. According to Heimark, the new tins are an “elegant solution to a difficult problem” and “an important step in PLUS continuing to make cannabis safe and approachable.”

Finally, PLUS has one of the largest food-grade manufacturing plants in the state. Currently, the factory, located in Adelanto, California, is 12,000 square feet with an annual production capacity of $50 million. The square footage is anticipated to reach 40,000 square feet with a $450 million production capacity upon completion of phase III. During the production process, gummy and mint products are manufactured, and dosage is tested twice internally at the factory and two more times by an independent lab. The company has strategically placed itself in the most competitive cannabis market in order to prove itself to be the leading edibles brand.

Plus Products’ first quarter 2019 sales marked a 4.9 percent increase over the fourth quarter of 2018, bringing retail sales to $10.84 million. Private placement offerings of convertible debentures earlier this year raised $17.9 million in capital. PLUS continues to invest in talent, market share, infrastructure and financial capacity as it looks forward to continued growth.

For more information, visit the company’s website at www.PlusProducts.com

NOTE TO INVESTORS: The latest news and updates relating to PLPRF are available in the company’s newsroom at http://ibn.fm/PLPRF

• Innovative Properties officially changed its name to Nabis Holdings Inc.
• Nabis Holdings continues to pursue investment in high-performing operators in the cannabis industry
• The company purchased assets from PDT Technologies to expand its production and licensing capabilities

Nabis Holdings (CSE: NAB) (OTC: INNPF) (FRA: 71P), a Canadian investment company pursuing interests in high-quality cash-flow assets in real estate, securities, cryptocurrency and all branches of the cannabis sector, has undergone a name change. Nabis Holdings will continue its focus on strategic revenue generation by investing in successful vertically integrated operators.

Effective May 6, 2019, the company formerly known as Innovative Properties officially changed its name to Nabis Holdings Inc. This name change resonates with the company’s motto – one team, one goal – while na bis translates to “repeat performance” or “encore.”

To continue expanding its production and licensing capabilities, Nabis Holdings recently announced completion of a previously announced purchase of assets from PDT Technologies (“PDT”). These assets include extraction and production equipment, as well as the right to lease PDT’s current production facility in Port Townsend, Washington.

This purchase signifies a promising opportunity for Nabis Holdings, and the company plans to spend approximately $3 million to expand the newly acquired production facility, which currently specializes in high-grade cannabis concentrate production. This expansion project will include “highly specialized equipment, two new extraction lines, [and] an extraction clean room and lab facility capable of producing up to 20,500 KG of cannabis concentrate on an annual basis.”

“We are thrilled to officially enter Washington State with the purchase of PDT’s certain assets,” Nabis Holdings CEO and Director Shay Shnet stated in a news release (http://ibn.fm/hQiAJ). “Washington represents the successful execution of another promising opportunity that will expand our production and licensing capabilities. We remain committed to our aggressive expansion plans, as we evaluate other opportunities in limited-license states that align with the company’s multistate cannabis expansion strategy.”

Nabis Holdings has been pursuing investment opportunities in a myriad of industries but seeks to establish an anchor investment portfolio by focusing on high-quality U.S. cannabis assets and brands that have proven themselves profitable. Once the company completes these acquisitions, Nabis Holdings actively assists the investees to implement standards and consistency, thus enhancing the existing business operations. Nabis seeks to be a leading investor in a diverse portfolio of vertically integrated multistate operations, including companies that are distributing nationally but with global ambitions.

For more information, visit the company’s website at www.NabisHoldings.com

NOTE TO INVESTORS: The latest news and updates relating to INNPF are available in the company’s newsroom at http://ibn.fm/INNPF

• Hemp seed genetics are critical to hemp farming success
• Cannabigerol (CBG) is emerging as a valuable cannabinoid with multiple potential health benefits
• Hemptown USA is growing one million rare cannabigerol-dominant plants designed to yield up to one million pounds of CBG biomass

High quality seeds are a key prerequisite for growing healthy, strong cannabis plants. The right seeds can deliver the right cannabinoid profile, increase resilience and help for achieving sufficiently sustainable yields.

Companies like Hemptown USA are pioneers in the farming of novel cannabinoid strains in addition to cannabidiol (CBD). In 2019, the company acquired $5.5 million worth of Oregon CBD Seeds, including one million rare cannabigerol (CBG) seeds. Planted in early May, these seeds are now scheduled for soil transplant in early June.

Growing demand and legislative changes like the passing of the federal Farm Bill are changing the cannabis industry. Leading seed genetics like the ones being grown by Hemptown USA allow for new strains that can be bred to produce various novel cannabinoids while maintaining the broad-spectrum appeal of the plant. This also allows for diverse corporate portfolios through the creation of products featuring distinct formulations.

Dealing with the THC Issue

Tetrahydrocannabinol (THC) is typically found in full-spectrum expression of cannabis plants. Despite the legalization of THC cannabis products at the state level, there is a large base of consumers who prefer to forego the high provided by THC and focus on the wellness benefits of non-psychoactive cannabinoids like CBD.

Historically, hemp types are grown for the production of seed and fiber (http://ibn.fm/J23gn). They contain low amounts of THC, and, over the years, they emerged as a reliable source of non-psychoactive CBD (http://ibn.fm/GGd0l). In the U.S., hemp is defined as cannabis that features 0.3 percent THC or less. For the emerging consumer, hemp can now be engineered to maintain low THC while producing exceedingly high cannabinoid levels.

Achieving Higher CBD Content

The plant’s DNA produces different types of proteins and enzymes that are responsible for the synthesis of CBD and THC. Plants that produce a lot of CBD feature more of the enzymes or proteins responsible for CBD synthesis (http://ibn.fm/IV19L). Hence, it’s easy to see how genetically superior seeds can produce large quantities of CBD and minimal concentrations of THC.

Genetic work has already enabled the development of strains that produce consistently high levels of either THC or CBD. Once plants with desirable traits are identified, they can be bred to express the new genetics. This mechanism works for boosting CBD production, but it can also be used to accomplish much more – high yields, resistance, etc.

Why CBG Will Play as Important a Role as CBD in the Near Future

While the industry has thus far been focused on CBD, cannabigerol, or CBG, is also emerging as a valuable cannabinoid. Non-intoxicating and present in relatively low concentrations in cannabis strains, CBG is the parent of both CBD and THC, hence the nickname “mother of all cannabinoids”. The market price for CBG oil in the U.S. is presently four to five times that of CBD.

The full range of effects is currently being studied, but, so far, CBG, known for its anti-inflammatory and anti-microbial benefits, has exhibited potent anti-cancer properties (http://ibn.fm/pafod), in addition to anti-depressive effects and benefits in the treatment of glaucoma and inflammatory bowel disease.

Through Hemptown USA’s “soil to oil to shelf” methodology, the company will be producing broad-spectrum CBD and CBG crudes, distillates, pure isolates, multiple cannabinoid formulations and branded products. This year’s CBG focus positions Hemptown as a leading CBG producer in the U.S. in 2019 and beyond. In addition to the Oregon farm, the company is also growing in Kentucky and Colorado. Its present footprint comes in at just over 1,500 acres, but plans are in place to scale up operations by 2020 – expanding cultivation to 2,500 acres and increasing potential revenues up to $200 million.

While the market is currently focused on CBD-producing plants, some are already eyeing the opportunities that CBG brings to the table. Forecasts suggest that CBG could rival CBD in the years to come and turn into the market’s next big thing. As societal attitudes toward medicinal and recreational cannabis products continue evolving, further changes and faster growth are both to be anticipated.

For more information, visit the company’s website at www.HemptownUSA.com

• CIIX CEO Warren Wang’s FY2020 projections are driven by forecasts of increased sales of CBD and planned merger/acquisition activities in Asian markets
• CIIX is also exploring retail space and expanding targeted advertising
• CIIX’s core revenue source is educational services for the Chinese-speaking investment community, including websites, radio and TV

ChineseInvestors.com Inc. (OTCQB: CIIX) CEO Warren Wang projects that the company’s sales will reach $11-12 million in FY2020, the 12 months ending in May 2020. Wang made the projection in a wide-ranging interview on the Redchip Money Report with host Dave Gentry, broadcast on YouTube (http://ibn.fm/hXpNa).

While CBD plays an important role in the growth of CIIX, Wang reminded viewers that the diverse company has numerous services focusing on delivering daily financial investment news through its online information portal, radio and TV shows, as well as online/offline cryptocurrency investment classes. The company’s website, ChineseFN.com (http://ibn.fm/EvtZN), has a following of more than 100,000 registered users and 5,000 subscribers.

Wang is also optimistic about the future of CBD, noting, “We believe this is like the dot com (boom) in 1993, with CBD products booming, and there is a lot of chance for us to enter into this market.” He noted CIIX’s opening of a pop-up kiosk in the Glendale (California) Galleria Mall (http://ibn.fm/nBT92) as an example of the company’s plans to grow.

“There are over four million Chinese Americans and Chinese Canadians in North America,” Wang continued. “Our growth plan is to try to use different advertising methods to open the retail shop to expand our sales.” To that end, Wang said that CIIX is expanding its advertising budget to focus on campaigns focused on holiday gift-giving events, such as Mother’s Day and Father’s Day.

Internationally, Wang indicated that the company is eyeing acquisition/merger activity in the Asian marketplace in the future.

CIIX is a diverse company that offers its audience of Chinese-speaking investors real-time market commentary, analysis and education-related services in Chinese character language sets.

For more information, visit the company’s website at www.ChineseInvestors.com

NOTE TO INVESTORS: The latest news and updates relating to CIIX are available in the company’s newsroom at http://ibn.fm/CIIX